Patents by Inventor Benjamin Reubinoff
Benjamin Reubinoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10174285Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.Type: GrantFiled: December 14, 2015Date of Patent: January 8, 2019Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Sharona Cohen Evenram, Benjamin Reubinoff
-
Publication number: 20180080007Abstract: The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.Type: ApplicationFiled: November 29, 2017Publication date: March 22, 2018Inventors: Michal Aharonowiz, Ofira Einstein, Benjamin Reubinoff, Tamir Ben-Hur
-
Patent number: 9862925Abstract: The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.Type: GrantFiled: October 29, 2008Date of Patent: January 9, 2018Assignee: Hadasit Medical Research Services & Development LimitedInventors: Michal Aharonowiz, Ofira Einstein, Benjamin Reubinoff, Tamir Ben-Hur
-
Publication number: 20160097032Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.Type: ApplicationFiled: December 14, 2015Publication date: April 7, 2016Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Sharona COHEN EVENRAM, Benjamin REUBINOFF
-
Patent number: 9243225Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.Type: GrantFiled: September 27, 2011Date of Patent: January 26, 2016Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Sharona Cohen Evenram, Benjamin Reubinoff
-
Patent number: 9005965Abstract: Provided are systems and methods for providing human cell cultures. Further provided are cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.Type: GrantFiled: January 13, 2011Date of Patent: April 14, 2015Assignee: Hadasit Medical Research Services & Development LimitedInventors: Etti Ben Shushan, Shelly Tannenbaum, Pavel Itsykson, Eyal Banin, Benjamin Reubinoff
-
Patent number: 8956866Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.Type: GrantFiled: April 27, 2008Date of Patent: February 17, 2015Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Masha Idelson, Ruslana Alper-Pinus, Alex Obolensky, Eyal Banin, Benjamin Reubinoff
-
Patent number: 8940537Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasalâ„¢ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.Type: GrantFiled: January 25, 2012Date of Patent: January 27, 2015Assignee: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Debora Steiner
-
Patent number: 8735149Abstract: Provided is a method for directing differentiation of neural progenitors with a caudal and ventral specification into motor neurons including culturing neural progenitors in a culturing medium including a basic medium supplemented by at least one inhibitor of the Notch signaling pathway whereby the neural progenitors differentiate into postmitotic motor neurons. The resulting motor neurons may be used for drug development, as carriers, e.g. for gene therapy of protein delivery as well as for transplantation for the purpose of treating a motor neuron disease.Type: GrantFiled: April 5, 2009Date of Patent: May 27, 2014Assignee: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Etti Ben Shushan, Michal Aharonowiz
-
Patent number: 8597947Abstract: The present application discloses methods expanding SCs in an undifferentiated state, the methods comprising incubating undifferentiated SCs in suspension within a culture system comprising basic medium and knockout serum replacement (KOSR). The methods may also be applicable for selective spontaneous or directed differentiation of SCs into a selected population of somatic cells from a culture system of SCs in suspension, the method further comprising incubating said undifferentiated SCs in culture system that support respectively, spontaneous or directed differentiation of SCs into the selected population of somatic cells. The present application also discloses a culture system for expansion of stem cells (SCs) comprising a suspension of undifferentiated stem cells within basic medium and knockout serum replacement (KOSR). The methods and culture system of the invention may be used for large scale production of differentiated cells.Type: GrantFiled: April 2, 2007Date of Patent: December 3, 2013Assignee: Hadasit Medical Research Services & Development LimitedInventor: Benjamin Reubinoff
-
Publication number: 20130280218Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.Type: ApplicationFiled: September 27, 2011Publication date: October 24, 2013Applicant: Hadasit Medical Research Services & Development LimitedInventors: Sharona Cohen Evenram, Benjamin Reubinoff
-
Publication number: 20120122209Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasalâ„¢ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Debora Steiner
-
Publication number: 20110189135Abstract: The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.Type: ApplicationFiled: October 29, 2008Publication date: August 4, 2011Inventors: Michal Aharonowiz, Ofira Einstein, Benjamin Reubinoff, Tamir Ben-Hur
-
Publication number: 20110177594Abstract: Provided are systems and methods for providing human cell cultures. Further provided are cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.Type: ApplicationFiled: January 13, 2011Publication date: July 21, 2011Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Etti Ben SHUSHAN, Shelly TANNENBAUM, Pavel ITSYKSON, Eyal BANIN, Benjamin REUBINOFF
-
Publication number: 20110091927Abstract: The present invention provides a method for directing differentiation of neural progenitors with a caudal and ventral specification into motor neurons comprising culturing neural progenitors in a culturing medium comprising a basic medium supplemented by at least one inhibitor of the Notch signaling pathway whereby said neural progenitors differentiate into postmitotic motor neurons. The resulting motor neurons may be used for drug development, as carriers, e.g. for gene therapy of protein delivery as well as for transplantation for the purpose of treating a motor neuron disease.Type: ApplicationFiled: April 5, 2009Publication date: April 21, 2011Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Benjamin Reubinoff, Etti Ben Shushan, Michal Aharonowiz
-
Publication number: 20110027333Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.Type: ApplicationFiled: April 27, 2008Publication date: February 3, 2011Applicant: Hadasit Medical Research Services and Development Ltd.Inventors: Masha Idelson, Ruslana Alper-Pinus, Alex Obolensky, Eyal Banin, Benjamin Reubinoff
-
Publication number: 20100093091Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasalâ„¢ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.Type: ApplicationFiled: September 30, 2009Publication date: April 15, 2010Applicant: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Debora Steiner
-
Publication number: 20090104695Abstract: The present invention concerns systems and methods for providing human cell cultures. Specific embodiments of the invention relate to cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.Type: ApplicationFiled: December 29, 2005Publication date: April 23, 2009Inventors: Etti Ben Shushan, Shelly Tannenbaum, Pavel Itsykson, Eyal Banin, Benjamin Reubinoff
-
Publication number: 20070212777Abstract: The present application discloses methods expanding SCs in an undifferentiated state, the methods comprising incubating undifferentiated SCs in suspension within a culture system comprising basic medium and knockout serum replacement (KOSR). The methods may also be applicable for selective spontaneous or directed differentiation of SCs into a selected population of somatic cells from a culture system of SCs in suspension, the method further comprising incubating said undifferentiated SCs in culture system that support respectively, spontaneous or directed differentiation of SCs into the selected population of somatic cells. The present application also discloses a culture system for expansion of stem cells (SCs) comprising a suspension of undifferentiated stem cells within basic medium and knockout serum replacement (KOSR). The methods and culture system of the invention may be used for large scale production of differentiated cells.Type: ApplicationFiled: April 2, 2007Publication date: September 13, 2007Inventor: Benjamin Reubinoff
-
Publication number: 20060078543Abstract: The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. This invention provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and cells that are generated along the pathway of neural differentiation may be used for: the study of the cellular and molecular biology of human neural development, discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, drug discovery and the development of screening assays for teratogenic, toxic and neuroprotective effects.Type: ApplicationFiled: September 29, 2005Publication date: April 13, 2006Inventors: Benjamin Reubinoff, Martin Pera, Tamir Ben-Hur